- Home
- KZIA vs BOLT Comparison
KZIA vs BOLT Comparison
Compare KZIA & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- BOLT
- Stock Information
- Founded
- KZIA 1994
- BOLT 2015
- Country
- KZIA Australia
- BOLT United States
- Employees
- KZIA N/A
- BOLT N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- BOLT Health Care
- Exchange
- KZIA Nasdaq
- BOLT Nasdaq
- Market Cap
- KZIA 9.0M
- BOLT 10.4M
- IPO Year
- KZIA 1999
- BOLT 2021
- Fundamental
- Price
- KZIA $7.20
- BOLT $6.17
- Analyst Decision
- KZIA Strong Buy
- BOLT Buy
- Analyst Count
- KZIA 3
- BOLT 3
- Target Price
- KZIA $16.00
- BOLT $47.50
- AVG Volume (30 Days)
- KZIA 299.1K
- BOLT 33.8K
- Earning Date
- KZIA 11-14-2025
- BOLT 11-11-2025
- Dividend Yield
- KZIA N/A
- BOLT N/A
- EPS Growth
- KZIA N/A
- BOLT N/A
- EPS
- KZIA N/A
- BOLT N/A
- Revenue
- KZIA $1,549,158.00
- BOLT $4,167,000.00
- Revenue This Year
- KZIA N/A
- BOLT N/A
- Revenue Next Year
- KZIA $49.25
- BOLT N/A
- P/E Ratio
- KZIA N/A
- BOLT N/A
- Revenue Growth
- KZIA 248983.08
- BOLT N/A
- 52 Week Low
- KZIA $2.86
- BOLT $4.59
- 52 Week High
- KZIA $39.05
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- KZIA 43.08
- BOLT 63.23
- Support Level
- KZIA $6.20
- BOLT $5.13
- Resistance Level
- KZIA $7.61
- BOLT $6.20
- Average True Range (ATR)
- KZIA 0.48
- BOLT 0.32
- MACD
- KZIA -0.06
- BOLT 0.07
- Stochastic Oscillator
- KZIA 47.57
- BOLT 87.19
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.